Dermatology

Your Article Summary

See Latest Articles

Off-label indications for imiquimod
Dermatology Online Journal, 06/25/09

Ganjian S et al. - Imiquimod has rapidly been recognized as a potential candidate for off-label use. Although the FDA has approved imiquimod only for the treatment of external genital and perianal warts, actinic keratoses, and superficial basal cell carcinoma, successful clinical studies teach the greater potential and efficacy of imiquimod in treating more cutaneous viral lesions.

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09

Topical Pimecrolimus: A Review of its Use in the Management of Pediatric Atopic Dermatitis
Pediatric Drugs, 11/06/09

Clinical Importance of Purulence in Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections
Journal of the American Board of Family Medicine, 11/09/09

See All of Clinical Pharmacology

Today in Dermatologic Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Childhood melanoma
Clinics in Dermatology, 11/04/09

Unusual variants of malignant melanoma
Clinics in Dermatology, 11/06/09

A Multimarker Prognostic Assay for Primary Cutaneous Melanoma
Clinical Cancer Research, 11/06/09

See All of Dermatologic Oncology

Today in Dermatopathology...keeping you current

Receive free subspecialty "5-minute updates" via email

Erysipeloid: a review
Clinical and Experimental Dermatology, 09/18/09

Update on oral lichen planus
Expert Review of Dermatology, 10/14/09

Childhood melanoma
Clinics in Dermatology, 11/04/09

See All of Dermatopathology